KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated

KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated

KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
Active Comparator: Potassium Nitrate

Randomized to KNO3

KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if tolerating well.
Placebo Comparator: Potassium Chloride

Randomized to KCl

Total

Sex: Female, Male

Race/Ethnicity, Customized

Class II- Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Class III- Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.

New York Heart Association Heart failure classification (NYHA Class) n (%)

Body Mass Index, kg/m^2, mean (SD)

Number of Obese Participants, n(%)

Number of Hypertensive Participants, n(%)

Number of Participants with Hyperlipidemia, n (%)

Number of Participants with Coronary Artery Disease, n (%)

Number of Participants with History of atrial fibrillation, n (%)

Number of Participants with Diabetes Mellitus, n (%)

Number of Participants with Obstructive sleep apnea, n (%)

Number of Participants with Current Continuous Positive Airway Pressure (CPAP) use, n (%)

Number of Participants with Obstructive lung disease, n (%)

Number of Participants on Beta-blockers, n (%)

Number of Participants onACEI/ARB, n (%)

Number of Participants on Mineralocorticoid receptor antagonists, n (%)

Number of Participants on Calcium-channel blockers, n (%)

Number of Participants on Loop diuretics, n (%)

Number of Participants on Thiazide diuretic, n (%)

Number of Participants on Statin, n (%)

Estimated Glomerular Filtration Rate (eGFR), mL/min per 1.73m^2, mean (SD)

Estimated Glomerular Filtration Rate (eGFR) <60 mL/min per 1.73m^2, n (%)

N-terminal pro-brain natriuretic peptide (NT-proBNP), pg/ml, mean (SD)

Number of Participants with high N-terminal pro-brain natriuretic peptide (NT-proBNP), pg/ml, n (%)

Hemoglobin, g/dL, mean (SD)

Methemoglobin, %, mean (SD)

Left Ventricular (LV) mass,g, mean (SD)

Left Ventricular (LV) mass index, g/m^2, mean (SD)

The ratio of twice LV diastolic posterior wall thickness to left ventricular end-diastolic dimension

Relative wall thickness, mean (SD)

Mitral early inflow velocity (E), cm/s, mean (SD)

Mitral atrial inflow velocity (E), cm/s, mean (SD)

Septal tissue doppler early velocity (e'), mm/s, mean (SD)

Septal E/e' ratio, mean (SD)

Left atrial volume index, mL/m^2, mean (SD)

Left ventricular ejection fraction, %, mean (SD)

Peak oxygen uptake (VO2) defined as the average value obtained during the last 30 seconds of exercise.

Change in Peak Oxygen Uptake (VO2) From Baseline Upto 1 Week of Administration for Each Dose

Percent change in peak vascular resistance from rest to peak exercise

Change in Vasodilatory Reserve for Each Dose

Percent change in oxidative capacity (oxyhemoglobin levels) before and after occlusion

Change in Mitochondrial Oxidative Capacity for Each Dose

Percent change in augmentation index, whereas augmentation index at each time point (visit) is defined as the amplitude of the second peak to the first peak of the aortic pulse wave form multiplied by 100: augmentation index = (P2/P1)×100.

Change in Aortic Augmentation Index

KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated.
Active Comparator: Potassium Nitrate (KNO3)

KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated.
Placebo Comparator: Potassium Chloride (KCl)

Overall Study

Julio Chirinos

Heart Failure

Diastolic Heart Failure

KNO3

Hospital of the University of Pennsylvania

Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF

University of Pennsylvania

methemoglobinemia

калијум

potassium

methemoglobinemia/калијум

Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF

Најкомплетнија база лековитог биља подржана науком